基本信息
浏览量:55
职业迁徙
个人简介
Date of birth: August 27th, 1959
Nationality: Italy
Work address: Institute of Oncology Research (IOR), Via Chiesa 5, 6500, Bellinzona, CH
Work phone: + 41 58 666 7214
Email: pina.carbone@ior.usi.ch
Dr. Carbone is a medical researcher focused on basic and translational research. Her group has a long-term interest in ETS transcription factors and their role in prostate cancer progression.
Research Focus:
Novel in vivo models to study the role of the ETS factor ESE3/EHF
The team has been the first to point that ESE3/EHF (member of the sub-family of epithelial-specific ETS transcription factors, endogenously expressed in many epithelial tissues) is involved in prostate epithelial cell differentiation, transcriptional and phenotypic reprogramming, and that its loss leads to acquisition of stem-like and tumorigenic properties. A recent accomplishment of the group is the production of the first mouse model with prostate conditional knockout of ESE3/EHF. Molecular and functional characterization of this model is ongoing in the laboratory by integrating molecular studies with multiomic approaches.
Epigenetics and progression of ERG fusion positive tumors
The laboratory focuses on gene fusions involving the ETS transcription factor ERG (TMPRSS2:ERG), very frequent in prostate cancer. An important notion recently emerged is that ERG requires the cooperation of other transcription factors and epigenetic regulators to fully exert its oncogenic potential. The team contributed to this new paradigm providing compelling evidence of a novel molecular mechanism of ERG activation based on EZH2-induced ERG methylation. The group defined the relevance of this post-translational modification and its impact in driving disease evolution towards the metastatic and castration resistant status. These studies are also providing new insights for developing more effective therapies for aggressive prostate tumors.
Circulating exosomes: novel biomarkers in prostate cancer
The group reported that ETS transcription factors directly control a network of microRNAs. This analysis led to discovery of a novel axis involving loss of ESE3/EHF and upregulation of a microRNA, miR-424, leading to increased stemness and tumorigenic potential of prostate cancer cells. Moreover, the group found that miR-424 is released by tumor cells in small extracellular vesicles or exosomes circulating in blood of patients with more advanced and aggressive prostate cancers. Exosomes are relevant means for transferring signals across cells and can facilitate the propagation of oncogenic stimuli promoting disease evolution and metastatic spread in cancer patients. Exosomes containing miR-424 induced stem-like traits and tumor-initiating properties in prostate epithelial cells and their administration by intravenous injection, mimicking their blood circulation in patients, promoted tumor growth in mouse xenograft models. These data identify a novel mechanism that promotes prostate cancer progression through exosome-mediated transfer of potent oncogenic effectors like miR-424 to other cells in the surrounding microenvironment or at distant metastatic sites. These findings might suggest novel approaches for the management and treatment of prostate cancer.
Supervision of junior researchers at graduate and postgraduate level:
Post-doctoral: 26. PhD student: 16. Undergraduate that completed training: 24.
Short Stage: 1.
Teaching activities:
Thesis committees and supervision of graduate and undergraduate students:
La Trobe University, Australia
University of Geneva, Switzerland
University of Lausanne, Switzerland
University of Milan, Milan, Italy
University of Insubria, Varese, Italy
International conferences (chaired sessions and presentations):
UVA Cancer Center Seminar, 2021, A War of ETS : new perspectives on prostate cancer progression, University of Virginia, Charlottesville, USA.
EPOP Scientific meeting, 2021, From ETS factors to exosomes: linking epigenetics and tumor microenvironment, Instituto Portugues de Oncologia do Porto, Porto, Portugal.
ICGEB workshop, 2018, ETS transcription factors in prostate cancer, University of Capetown, South Africa.
ESUR meeting, Paris,2017. MiRNA in prostate cancer. Plenary section talk.
EAU 2017, London 2017. Thematic session, Personalised approach to antagonizing ERG in prostate cancer.
EAU 2017, London 2017. Session chair.
EAU 2017, London 2017. State of the art lecture, Epithelial to mesenchymal transition in prostate cancer.
ESUR meeting, Glasgow 2014, ETS transcription factors, cell differentiation and stemness in prostate cancer.
研究兴趣
论文共 134 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Alessia Cacciatore,Dheeraj Shinde, Carola Musumeci,Giada Sandrini,Luca Guarrera,Domenico Albino, Gianluca Civenni, Elisa Storelli,Simone Mosole, Elisa Federici, Alessio Fusina,Marta Iozzo,Andrea Rinaldi,Matteo Pecoraro,Roger Geiger,Marco Bolis,Carlo V Catapano,Giuseppina M Carbone
Nature Communicationsno. 1 (2024): 1-25
crossref(2023)
crossref(2023)
crossref(2023)
pubmed(2023)
crossref(2023)
crossref(2023)
crossref(2023)
加载更多
作者统计
#Papers: 134
#Citation: 3044
H-Index: 28
G-Index: 54
Sociability: 6
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn